A statement released earlier today by Zacks Investment Research about Charles River Laboratories Intl. Inc (NYSE:CRL) bumps the target price to $93.00
- Updated: October 8, 2016
Stating a potential upside of 0.12%, Zacks Investment Research upped the price target of Charles River Laboratories Intl. Inc (NYSE:CRL) to $93.00
Having a price of $82.97, Charles River Laboratories Intl. Inc (NYSE:CRL) traded -0.31% lower on the day. With the last close up 0.42% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Charles River Laboratories Intl. Inc has recorded a 50-day average of $82.37 and a two hundred day average of $82.70. Volume of trade was down over the average, with 288,586 shares of CRL changing hands under the typical 335,437
With a total market value of $0, Charles River Laboratories Intl. Inc has price-earnings ratio of 28.05 with a one year low of $63.68 and a one year high of $89.18 .
A total of 15 analysts have released a research note on Charles River Laboratories Intl. Inc. Six analysts rating the company a strong buy, three analysts rating the company a buy, eight analysts rating the company a hold, two analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $85.47.
More About Charles River Laboratories Intl. Inc (NYSE:CRL)
Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services. It has developed a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.